Russian researchers have announced the results of clinical trials for a new drug to treat Ankylosing Spondylitis, a chronic inflammatory disease that affects the spine. Conducted over 48 weeks with 260 patients, the study demonstrated significant improvements starting from the first week and continuing through the end of the trial. Developed in collaboration with Biocad, a Russian pharmaceutical company, the drug was created by the renowned Pirogov Russian National Research Medical University and the esteemed Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, both highly respected institutions in the field of medicine.
Russian scientists have developed a monoclonal antibody that has the potential to slow down and stop the immune-inflammatory process, offering the prospect of preventing the progression of axial spondyloarthritis (Bechterew’s disease). Unlike current treatment options, this drug targets the root cause of the disease, rather than just treating the symptoms of immune inflammation. The drug was registered by the Russian Ministry of Health on April 24, 2024.
